Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Real4Reg

Financiado

Cerrado

Development, optimisation and implementation of artificial intelligence methods...

Development, optimisation and implementation of artificial intelligence methods for real world data analyses in regulatory decision-making and health technology assessment along the product lifecycle Real-world evidence derived from real-world data (RWD) has a promising role to inform regulatory decision-making. Based on highly relevant use cases from regulatory practice and across the product lifecycle Real4Reg develops AI-ba... ver más

31/12/2026

BUNDESINSTITUT FUR...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPR... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-01

HORIZON-HLTH-2022-TOOL-11-01: Optimising effectiveness in patient... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

BUNDESINSTITUT FUR ARZNEIMIT...

Lider

Proyectos interesantes

REALM

Medical Technol...

Data Science

7M€ Cerrado

HTx

Medical Technol...

Data Science

10M€ Cerrado

UTILIZACIÓN DEL REAL-WORLD DATA PARA LA EVALU...

Medical Technol...

Data Science

231K€ Rechazado

UTILIZACIÓN DEL REAL-WORLD DATA PARA LA EVALU...

Medical Technol...

Data Science

195K€ Rechazado

More-EUROPA

Medical Technol...

Data Science

7M€ Cerrado

GETREAL

Medical Technol...

Data Science

17M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 47 meses Fecha Inicio: 2023-01-01
Fecha Fin: 2026-12-31

Líder del proyecto

BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPR... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Real-world evidence derived from real-world data (RWD) has a promising role to inform regulatory decision-making. Based on highly relevant use cases from regulatory practice and across the product lifecycle Real4Reg develops AI-based data-driven methods and tools for the assessment of medicinal products. Findings will inform training activities on good practice examples and will be implemented in existing and emerging guidelines for both health regulatory authorities and health technology assessment (HTA) bodies across Europe. There is urgent need to enable the use and establish the value of the application of RWD across the spectrum of regulatory use cases. The use of RWD is established in regulatory processes such as safety monitoring, but evidentiary value for further use cases, especially in the pre-authorisation and evaluation phase of medicinal products, is rudimentary. The use of RWD in post-authorisation steps is constrained by data variability and by challenges in analysing data from different settings and sources. Thus, the development of new and optimised methods for RWD analyses is essential. Real4Reg addresses the challenges and opportunities of RWD analyses across different health care systems by involving multiple stakeholders to work together in a collaborative approach, also outreaching to already established European initiatives. Our consortium assembles partners with outstanding excellence in the field of RWD analyses, including experts from regulatory agencies/ HTA (BfArM, DKMA, Infarmed), academia (Fraunhofer, UEF, CSC, AU, DZNE) and patient organisations (EUpALS, EIWH). In an advisory board stakeholders provide input and guidance to the project, including patients, industry, payers, HTA bodies and healthcare professionals. The structure and approach of our project facilitates the successful implementation of the effective use of RWD in regulatory decision-making and HTA, and ultimately supports the application of better medicines for patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores